Lexaria Bioscience CEO Discusses Material Transfer Agreement and 2026 Research

Kelowna, British Columbia — May 7, 2026 — Leads & Copy — Lexaria Bioscience Corp. (NASDAQ:LEXX) has released the second episode of its investor communications series, Reformulated: Into the Mainstream.

The episode features CEO Rich Christopher in conversation with host Ana Berry. Discussions include the recently announced extension of Lexaria's Material Transfer Agreement with a global pharmaceutical partner through year-end 2026, the company's 2026 GLP-1 research priorities, and how ongoing business development activity fits within Lexaria's broader commercial strategy.

CEO Rich Christopher said the extension reflects continued engagement around DehydraTECH and the data expected to be generated this year. He added that the company's focus remains on producing compelling clinical evidence and expanding the dialogue with potential partners across GLP-1 and beyond.

Additional episodes will be released periodically, covering Lexaria's clinical pipeline, intellectual property portfolio, and developments across the oral drug delivery landscape.

DehydraTECH is Lexaria’s patented drug delivery formulation and processing platform technology. It improves the way a wide variety of drugs enter the bloodstream through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds an intellectual property portfolio with 65 patents granted and additional patents pending worldwide.

The second episode is available here: https://www.youtube.com/watch?v=WZaXvP-PpJM

Source: Lexaria Bioscience Corp.